Compare DexCom, Inc. (DXCM) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Johnson Controls International PLC — how do they compare? DexCom, Inc. trades at $77.41 (market cap $28.06B), while Johnson Controls International PLC trades at $140.68 (market cap $87.10B). The key difference: Johnson Controls International PLC is far larger — about 3.1× DexCom, Inc.'s market cap, and Johnson Controls International PLC pays a 1.12% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | JCI | |
|---|---|---|
Market Cap | $28.06B | $87.10B |
Sector | Health | Industrials |
52-Week High | $89.53 | $148.21 |
52-Week Low | $54.84 | $103.24 |
Enterprise Value | $27.03B | $95.93B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
JCI trades at $139.67, down 3.84% on the day, with a bullish technical signal from moving averages and support at $140. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.32. Revenue for 2025 was $23.60B, net income $3.29B, and profit margin expanded to 13.94%. Analyst consensus is strongly bullish with a $158.29 price target and no sell ratings among 45 analysts. Recent news highlights innovation awards and dividend declarations.
JCI presents a favorable outlook with consistent earnings beats, strong analyst support, and exposure to growth areas like energy efficiency. Risks include high valuation multiples (P/E 43.66) and increasing debt-to-asset ratio (26.06% in 2025). The stock's proximity to the $140 support level offers a potential entry point, but macroeconomic headwinds and execution risks in competitive markets warrant caution for investors seeking stable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
